{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:09:11Z","timestamp":1792613351443,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2026,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Total shoulder arthroplasty (TSA) is being performed with increasing frequency and is projected to rise further in the coming years. Although generally successful, the procedure carries inherent risks. Diabetes is a well-established risk factor for postoperative complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective antidiabetic agents that are widely used; however, their perioperative safety in the setting of TSA has not yet been evaluated. The objective of this study was to assess the effect of perioperative SGLT2i use on 90-day medical complications and 2-year implant-related complications in diabetic patients undergoing TSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The TriNetX database was queried to identify diabetic patients who underwent TSA. Patients were stratified according to SGLT2i prescription status, and 1:1 propensity score matching was done to adjust for relevant demographic and medical comorbidities. Outcomes of interest included 90-day medical and surgical complications and 2-year implant-related complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After propensity score matching, each cohort included 2,360 patients. The SGLT2i cohort demonstrated a significantly higher 90-day risk of myocardial infarction compared with control subjects (2.03% vs 0.89%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). No significant differences were observed between groups in the 90-day risk of ketoacidosis, deep vein thrombosis, pulmonary embolism, stroke, pneumonia, acute kidney injury, transfusion, wound disruption, sepsis, or hospital readmission. Similarly, there was no increased risk of implant-related complications at 2 years postoperatively in the SGLT2i cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>SGLT2i use was associated with an increased 90-day risk of myocardial infarction after TSA but appeared safe regarding implant-related outcomes. Additional research is warranted to clarify these associations; however, these findings may aid in preoperative counseling and optimization of surgical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>III<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-25-01211","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:05:13Z","timestamp":1776780313000},"page":"e2255-e2260","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["SGLT-2 Inhibitor Effects on Medical and Surgical Complication Rates After Total Shoulder Arthroplasty: A Propensity Matched Cohort Study"],"prefix":"10.5435","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-0064","authenticated-orcid":false,"given":"Tarek","family":"Haj Shehadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boufadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3845-7220","authenticated-orcid":false,"given":"Joseph A.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"R1-20260807","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jseint.2024.10.013","article-title":"Projections of utilization of primary and revision shoulder arthroplasty in the United States in the next 40 years","volume":"9","author":"Cecora","year":"2025","journal-title":"JSES Int"},{"key":"R2-20260807","first-page":"e21.00146","article-title":"Surgical complications after reverse total shoulder arthroplasty and total shoulder arthroplasty in the United States","volume":"5","author":"Ma","year":"2021","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"R3-20260807","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jse.2014.01.046","article-title":"Diabetes as a risk factor for poorer early postoperative outcomes after shoulder arthroplasty","volume":"23","author":"Ponce","year":"2014","journal-title":"J Shoulder Elbow Surg"},{"key":"R4-20260807","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jor.2023.03.003","article-title":"Diabetes increases risk for readmission and infection after shoulder arthroplasty: A national readmissions study of 113,713 patients","volume":"38","author":"Duey","year":"2023","journal-title":"J Orthop"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"Diabetes 2030: Insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul Health Manag"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12872-024-03961-5","article-title":"Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021","volume":"24","author":"Gonzalez","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"R8-20260807","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: From glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"key":"R9-20260807","article-title":"Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors. in StatPearls. Treasure Island, FL ineligible companies. Disclosure: Arun Mahtani declares no relevant financial relationships with ineligible companies. Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies","author":"Padda","year":"2025"},{"key":"R10-20260807","doi-asserted-by":"crossref","first-page":"e99123","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/anae.16461","article-title":"The peri-operative implications of sodium-glucose co-transporter 2 inhibitors: A narrative review","volume":"80","author":"Stewart","year":"2025","journal-title":"Anaesthesia"},{"key":"R12-20260807","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bja.2023.02.039","article-title":"Current practice in the perioperative management of patients with diabetes mellitus: A narrative review","volume":"131","author":"Crowley","year":"2023","journal-title":"Br J Anaesth"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1213\/ANE.0000000000006791","article-title":"Society for ambulatory anesthesia updated consensus statement on perioperative blood glucose management in adult patients with diabetes mellitus undergoing ambulatory surgery","volume":"139","author":"Rajan","year":"2024","journal-title":"Anesth Analg"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","article-title":"Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users","volume":"160","author":"Tallarico","year":"2025","journal-title":"JAMA Surg"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"856","DOI":"10.5435\/JAAOS-D-24-00299","article-title":"Patients with diabetes on sodium-glucose Cotransporter-2 inhibitors undergoing total knee arthroplasty are at increased odds for a number of postoperative adverse events but reduced risk of transfusion","volume":"33","author":"Kim","year":"2024","journal-title":"J Am Acad Orthop Surg"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jse.2024.07.045","article-title":"Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty?","volume":"34","author":"Elsabbagh","year":"2025","journal-title":"J Shoulder Elbow Surg"},{"key":"R17-20260807","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1161\/CIR.0000000000001024","article-title":"Diagnosis and management of patients with myocardial injury after noncardiac surgery: A scientific statement from the American heart association","volume":"144","author":"Ruetzler","year":"2021","journal-title":"Circulation"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","article-title":"Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis","volume":"160","author":"Dixit","year":"2025","journal-title":"JAMA Surg"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","article-title":"Adverse effects of SGLT2 inhibitors on bone health","volume":"14","author":"Blau","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-25-01211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:23Z","timestamp":1787668763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-25-01211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-25-01211","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2025-09-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}